These data are in concordance with our data demonstrating Met amplification in a subset of p53-null mammary tumours and highlight the potential utility of transplantable tumours 1203 and 1204 and the MMTV-Metmt;Trp53fl/+;Cre model generated by the Park group [69] as preclinical models in which to test Met-directed therapies for triple-negative breast cancer. The gene discussed is TP53; the disease is breast cancer.